0001104659-23-117365.txt : 20231113 0001104659-23-117365.hdr.sgml : 20231113 20231113174401 ACCESSION NUMBER: 0001104659-23-117365 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231108 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Jennifer Kayden CENTRAL INDEX KEY: 0001801372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 231400363 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Chien Jennifer DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm2330582-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-08 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001801372 Lee Jennifer Kayden 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 EVP, Head of North America 1 Common Stock 2023-11-08 4 M 0 5712 6.8 A 7359 D Common Stock 2023-11-08 4 S 0 3479 28.6429 D 3880 D Common Stock 2023-11-08 4 S 0 2233 29.3129 D 1647 D Common Stock 2023-11-09 4 M 0 3438 6.8 A 5085 D Common Stock 2023-11-09 4 S 0 1719 27.3712 D 3366 D Common Stock 2023-11-09 4 S 0 1719 28.00 D 1647 D Stock Option (Right to Buy) 6.80 2023-11-08 4 M 0 5712 0 D 2032-02-08 Common Stock 5712 61880 D Stock Option (Right to Buy) 6.80 2023-11-09 4 M 0 3438 0 D 2032-02-08 Common Stock 3438 58442 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee 2023-11-13